Table 3.
Equation performance overview in all patients and subgroups
| All patients | Stable patients n = 456 | Critically ill patients n = 87 | CKD category G1, GFR > 90 n = 101 |
G2, GFR 89–60 n = 172 | G3a–b, GFR 59–30 n = 213 | G4–5, GFR<30 n = 57 | |
|---|---|---|---|---|---|---|---|
| Accuracy P30 | |||||||
| PENK-Crea | 83 (80–86) | 85 (82–88) | 72 (63–81) | 79 (71–87) | 88 (84–93) | 86 (82–91) | 61 (49–74) |
| MDRD | 68 (64–72) | 68 (64–72) | 69 (59–78) | 47 (38–57) | 70 (63–77) | 75 (69–80) | 65 (53–77) |
| 2009 CKD-EPI | 76 (72–79) | 77 (73–80) | 69 (59–78) | 65 (56–75) | 82 (76–88) | 77 (71–83) | 68 (56–80) |
| 2021 CKD-EPI | 80 (77–83) | 80 (76–83) | 82 (73–89) | 87 (81–94) | 87 (82–92) | 79 (74–85) | 49 (36–62) |
| Bias and precision, mean ± SD | |||||||
| PENK-Crea | 0.5 ± 15 | −1 ± 13 | 8 ± 20 | 16 ± 14 | 0 ± 15 | −3 ± 11 | −8 ± 10 |
| MDRD | 8 ± 17 | 7 ± 15 | 9 ± 24 | 24 ± 19 | 8 ± 17 | 3 ± 10 | 6 ± 9 |
| 2009 CKD-EPI | 5 ± 17 | 4 ± 14 | 11 ± 20 | 22 ± 15 | 4 ± 15 | 1 ± 11 | −6 ± 9 |
| 2021 CKD-EPI | 1.3 ± 16 | 0.5 ± 15 | 6 ± 19 | 17 ± 15 | 1 ± 15 | −2 ± 12 | −8 ± 10 |
CKD, chronic kidney disease; CKD-EPI, chronic kidney disease-epidemiology collaboration; MDRD, modification of diet in renal disease.
Bias and precision were calculated using mGFR minus eGFR, thus a positive bias represents an underestimation, and depicted in mean ± SD bias in ml/min/1.73 m2. The P30 accuracy represents the percentage of eGFR that is within a range of ±30% of the mGFR, and is depicted in percentages with 95% confidence interval.